Drug information

Audio
Download files:
drug-audio-en-3BNC117.mp3
Pronounce:
3BNC117
Other Names
GS-5423, TAB, teropavimab, 3BNC117-LS, 3BNC117-LS-J, (long-acting variants of 3BNC117)
Drug Class
Broadly Neutralizing Antibodies
Registry Number
1412902-17-0 (CAS)
Organization:
Rockefeller University; Gilead Sciences
Phase of Development

3BNC117-LS is in Phase 2 development as a broadly neutralizing antibody for HIV treatment. (A long-acting variant of 3BNC117 has also been studied for HIV prevention.)

(Compound details obtained from PubChem,1 Treatment Action Group website,2 Gilead Sciences press release,3 and ClinicalTrials.gov4)

What is 3BNC117?What is 3BNC117?

What is 3BNC117?

3BNC117 is an investigational drug that has been studied as a possible strategy to treat people with HIV. 3BNC117 belongs to a group of drugs called broadly neutralizing antibodies (bNAbs).2

Long-acting forms of 3BNC117, called 3BNC117-LS (also known as GS-5423 or teropavimab) and 3BNC117-LS-J, are currently under study for HIV treatment.2 A long-acting version of 3BNC117 has also been studied for HIV prevention.4

To learn how investigational drugs are tested during clinical trials, read the HIVinfo What is an Investigational HIV Drug? and HIV and AIDS Clinical Trials fact sheets.

How do broadly neutralizing antibodies work?How do broadly neutralizing antibodies work?

How do broadly neutralizing antibodies work?

Antibodies are proteins that the immune system makes to fight infection. A person with HIV produces specific antibodies against HIV. However, most of these antibodies do not stop HIV from multiplying in the body.5,6

Some people with HIV naturally produce rare types of HIV antibodies called broadly neutralizing antibodies (bNAbs). bNAbs are powerful antibodies that can work against different HIV strains. bNAbs can block HIV from entering healthy cells and activate other immune cells to help destroy infected cells.6–8

Researchers are investigating whether giving bNAbs to people with HIV can help them maintain undetectable levels of HIV without the need for daily antiretroviral therapy. Additionally, some bNAbs are being studied because they may be able to reduce the size of the latent HIV reservoir.7,9

Researchers have also studied bNAbs, such as 3BNC117, for HIV prevention.4,10 This record focuses on the study of 3BNC117 as a treatment for HIV.

Select clinical trials of 3BNC117Select clinical trials of 3BNC117

Select clinical trials of 3BNC117

Study Names: ROADMAP; NCT02850016

Phase: 2a
Status: This study has been completed.
Locations: Denmark, Germany, United States
Purpose: The purpose of this study was to compare the efficacy of the latency reversing agent romidepsin plus 3BNC117 to the efficacy of romidepsin alone on delaying or preventing viral rebound during an analytical treatment interruption of ART.11,12
Selected Study Results: Results published in The Lancet Microbe (2022) showed that romidepsin plus 3BNC117 and romidepsin given alone had no substantial effect on reducing latent HIV reservoir size in participants with viral suppression on ART. Also, romidepsin plus 3BNC117, compared to romidepsin given alone, was not effective in delaying the time to viral rebound during analytical treatment interruption.12

Study Names: eCLEAR; NCT03041012

Phase: 1b/2a
Status: This study has been completed.
Locations: Denmark and United Kingdom
Purpose: The purpose of this study was to evaluate whether giving romidepsin and/or 3BNC117 to treatment-naive individuals who were newly diagnosed with HIV and starting ART could reduce the time to viral suppression, limit the size of the latent HIV reservoir, and delay the time to viral rebound during an analytical treatment interruption of ART.13
Selected Study Results: Results presented at CROI 2022 and published in Nature Medicine (2022) showed that participants receiving 3BNC117, with or without romidepsin, had a faster decline in viral load than participants receiving ART only. Also, 3BNC117 significantly enhanced the elimination of infected cells after participants started ART, compared to what was seen in participants receiving ART only. After 1 year, latent HIV reservoir size was reduced from baseline in all treatment groups, with the greatest reduction seen in people receiving 3BNC117 plus ART.14,15

Study Names: TITAN; NCT03837756

Phase: 2a
Status: This study has been completed.
Locations: Australia, Denmark, Norway, United States
Purpose: The purpose of this study was to evaluate the safety of lefitolimod and the bNAbs 3BNC117 and 10-1074 and to evaluate whether this combination could delay the time to viral rebound during an analytical treatment interruption of ART.16
Selected Study Results: Results published in Nature Medicine (2023) and presented at CROI 2023 showed that the groups receiving dual bNAb treatment had a significant delay in the time to viral rebound during an analytical treatment interruption of ART, as compared to groups receiving placebos only or lefitolimod plus placebo. The addition of lefitolimod to dual bNAb treatment did not have any additional effect on viral control compared to dual bNAb treatment alone.17,18

Study Name: NCT03719664

Phase: 2
Status: The status of this study is unknown.
Location: United States
Purpose: The purpose of this study is to determine the most effective dose of 3BNC117 and the investigational fusion inhibitor albuvirtide and evaluate the safety and effectiveness of this combination as long-acting maintenance treatment.19

Study Names: RIO; NCT04319367

Phase: 2
Status: This study is currently recruiting participants.
Location: Denmark and United Kingdom
Purpose: The purpose of this study is to determine whether the combination of the two long-acting bNAbs 3BNC117-LS and 10-1074-LS can prevent viral rebound during an analytical treatment interruption of ART.20
Selected Study Results: Results presented at CROI 2025 and published on MedRxiv (2026) showed that the combination of 3BNC117-LS and 10-1074-LS was significantly more effective than placebo in maintaining viral control in participants who had interrupted ART for up to 20 weeks. At Week 20, 75% of the participants who received bNAbs versus 11% of the participants who received placebo had not experienced viral rebound.21,22
Additional Published Material:

Study Name: NCT04819347

Phase: 2
Status: This study has been completed.
Location: China
Purpose: The purpose of this study was to evaluate the safety of combination therapy with albuvirtide plus 3BNC117 and assess whether this combination could control viral load levels during an analytical treatment interruption of ART.2,23

Study Name: NCT04560569

Phase: 2
Status: The status of this study is unknown.
Location: United States
Purpose: The purpose of this study is to evaluate the safety and efficacy of combination therapy with albuvirtide plus 3BNC117 added to ART in people who have multidrug-resistant HIV. Participants will continue on their existing failing ART regimen for 1 week and then will switch to an optimized background regimen for 24 weeks.24
Selected Study Results: Results presented at CROI 2025 showed that 10 participants had a substantial reduction in viral load from baseline after 1 week of treatment with albuvirtide plus 3BNC117 added to a failing ART regimen. At the end of treatment, 87.5% participants receiving albuvirtide plus 3BNC117 with an optimized background regimen achieved an undetectable viral load.25

Study Names: RHIVIERA-02; NCT05300035

Phase: 2
Status: This study is currently recruiting participants.
Location: France
Purpose: The purpose of this study is to evaluate whether the administration of the long-acting bNAbs 3BNC117-LS and 10-1074-LS in people with primary HIV infection who are starting ART can control viral load levels during an analytical treatment interruption of ART.26

Study Names: HIV-CORE 009; A5374; NCT06071767

Phase: 1/2a
Status: This study is currently recruiting participants.
Locations: United States and Brazil
Purpose: The purpose of this study is to evaluate the safety and efficacy of a combination regimen in adults who started suppressive ART during acute HIV. The combination regimen includes therapeutic HIV vaccines, the immune modulator vesatolimod, and the long-acting bNAbs 3BNC117-LS (GS-5423) and 10-1074-LS (GS-2872).27

Study Names: GS-US-536-5939; NCT05729568

Phase: 2
Status: This study is ongoing, but not recruiting participants.
Locations: United States, Australia, Canada, and Puerto Rico
Purpose: The purpose of this study is to evaluate the safety and efficacy of the bNAbs 3BNC117-LS (teropavimab; GS-5423) and 10-1074-LS (zinlirvimab; GS-2872) in combination with the capsid inhibitor lenacapavir as long-acting treatment.28
Selected Study Results: Results presented at CROI 2025 showed that 3BNC117-LS and 10-1074-LS plus lenacapavir given every 6 months had similar efficacy to daily oral ART in controlling viral load levels. At Week 26, 96% of participants in each group maintained viral suppression.29
Additional Published Material:

Study Names: ACACIA Study; ACTG A5417; NCT06205602

Phase: 2
Status: This study is currently recruiting participants.
Locations: Botswana and South Africa
Purpose: The purpose of this study is to evaluate the safety of the long-acting bNAbs 3BNC117-LS and 10-1074-LS and determine whether the combination of the two bNAbs can prevent viral rebound during an analytical treatment interruption of ART.30

Study Names: AbVax; NCT07054931

Phase: 2
Status: This study is currently recruiting participants.
Locations: United Kingdom
Purpose: The purpose of this study is to evaluate whether a combination regimen consisting of therapeutic HIV vaccines and the bNAbs 3BNC117-LS (teropavimab; GS-5423) and 10-1074-LS (zinlirvimab; GS-2872) can produce a lasting immune response in adults with viral suppression undergoing an analytical treatment interruption of ART.31

For more details on the studies listed above, see the Health Professional version of this drug summary.

Additional studies evaluating 3BNC117 for HIV treatment have been or are being conducted, including the following early-phase trials:

  • NCT03526848: A Phase 1b study that assessed whether 3BNC117 and 10-1074 could prevent viral rebound in adults with HIV during an analytical treatment interruption of ART. This study has been completed and results are available from Nature (2022).32
  • NCT04250636: A Phase 1 study that evaluated the safety, pharmacokinetics, and antiviral activity of single infusions of both 3BNC117-LS and 10-1074-LS in adults with HIV who were off ART. This study has been completed and results are available from CROI 2022.33
  • BEAT-2 (NCT03588715): A Phase 1 study that evaluated whether the immune modulator peginterferon alfa-2b plus 3BNC117 and 10-1074 could control viral rebound and reduce the latent HIV reservoir in adults with HIV during an analytical treatment interruption of ART. This study has been completed and main outcome results are available from CROI 2023.2,34
  • NCT04811040: A Phase 1b study that evaluated the safety and efficacy of 3BNC117-LS (teropavimab) and 10-1074-LS (zinlirvimab) in combination with the capsid inhibitor lenacapavir in controlling viral load levels in adults with HIV and viral suppression on ART. This study has been completed, and results are available from The Lancet HIV (2024), CROI 2024, and HIV Glasgow 2024. Results to a small study within the Phase 1b trial are available from J Infect Dis (2025).35
  • MCA-1031 (ES38918) (NCT05245292): A Phase 1 trial evaluating the safety and antiviral activity of 3BNC117-LS and 10-1074-LS in combination with N-803 (an investigational therapy based on the cytokine IL-15) in virologically suppressed adults with HIV during an analytical treatment interruption of ART. This study is ongoing, but not recruiting participants. Preliminary results are available from IAS 2025.36
  • NCT05612178: A Phase 1 study investigating the safety and efficacy of 3BCNC117-LS and 10-1074-LS on persistent viral reservoirs in people with HIV on suppressive ART. This study is ongoing, but not recruiting participants.37
  • ACTG A5416 (NCT06031272): A Phase 1 study evaluating the safety and antiviral activity of 3BNC117-LS-J and 10-1074-LS-J in virologically suppressed adults with HIV undergoing an analytical treatment interruption of ART. This study is ongoing, but not recruiting participants.38
  • NCT06908083: A Phase 1 trial evaluating the time to viral rebound during an analytical treatment interruption of ART in participants who participated in an earlier study (protocol MCA-1034) and received 3BNC117-LS and 10-1074-LS or placebo. This study is enrolling by invitation.39

What side effects might 3BNC117 cause?What side effects might 3BNC117 cause?

What side effects might 3BNC117 cause?

One goal of HIV research is to identify safe new drugs that have fewer side effects. The following side effects were observed in some of the studies of 3BNC117 listed above.

ROADMAP (NCT02850016)

In the ROADMAP trial, 11 participants received romidepsin plus 3BNC117 and nine participants received romidepsin alone. All participants in both groups experienced side effects, most of which were mild to moderate in severity. More drug-related side effects occurred with romidepsin than with 3BNC117.12

eCLEAR (NCT03041012)

In the eCLEAR study looking at the use of romidepsin and/or 3BNC117 in participants starting ART, most of the side effects that occurred were mild or moderate and unrelated to study treatments. Twenty-nine side effects, most of which were mild, were related to 3BNC117. The most common 3BNC117-related side effects were fatigue and headache.15

TITAN (NCT03837756)

In this Phase 2a trial, participants received placebo/placebo, lefitolimod/placebo, placebo/bNAbs, or lefitolimod/bNAbs. In total, 253 side effects were reported during the trial. Fourteen side effects were related to bNAb therapy—11 were mild, two were moderate, and one was severe. The severe bNAb-related side effect was an infusion-related reaction to 3BNC117 that got better with treatment. The most common side effect related to bNAb therapy was fatigue.17

RIO (NCT04319367)

In the Phase 2 RIO trial, participants received either up to two infusions of the bNAbs 3BNC117-LS and 10-1074-LS or placebo. No serious side effects related to the bNAbs were reported.21

NCT04560569

In this Phase 2 study, 16 participants completed treatment with albuvirtide plus 3BNC117 in combination with ART. The most common side effect was upper airway infection, which occurred in 25% of the participants. No serious side effects related to albuvirtide or 3BNC117 were reported.24,25

GS-US-536-5939 (NCT05729568)

In this Phase 2 study, participants either received the bNAbs 3BNC117-LS (teropavimab; GS-5423) and 10-1074-LS (zinlirvimab; GS-2872) in combination with lenacapavir or continued daily oral ART. Treatment-related side effects (not including injection site reactions) occurred in six participants in the bNAbs/lenacapavir group and included increased tears, device dislocation, abnormal dreams, and insomnia. There were no serious or severe treatment-related side effects associated with the bNAbs/lenacapavir regimen. Overall, the most common side effects were mild to moderate injection site reactions related to lenacapavir. No infusion-related reactions to either 3BNC117-LS or 10-1074-LS occurred.29

Because 3BNC117 is still being studied, information on possible side effects of the drug is not complete. As testing of 3BNC117 continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying 3BNC117?Where can I get more information about clinical trials studying 3BNC117?

Where can I get more information about clinical trials studying 3BNC117?

More information about 3BNC117-related research studies is available from ClinicalTrials.gov. (The ClinicalTrials.gov search can be modified so that you can get results that better match your interests.)

Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

ReferencesReferences

References

  1. National Center for Biotechnology Information. PubChem substance record for SID 381127297, 3BNC117, Source: ChemIDplus. Accessed March 5, 2026
  2. Treatment Action Group website. Research toward a cure trials. Accessed March 5, 2026
  3. Gilead Sciences: press release, dated January 9, 2020. Gilead Sciences licenses portfolio of HIV antibodies from The Rockefeller University. Accessed March 5, 2026
  4. International AIDS Vaccine Initiative. Safety and pharmacokinetics of the combination broadly neutralizing antibodies, 3BNC117-LS-J and 10-1074-LS-J, in healthy American and African adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 13, 2019. NLM Identifier: NCT04173819. Accessed March 5, 2026
  5. Snow B. The rise of broadly neutralizing antibodies. AIDS Vaccine Advocacy Coalition (AVAC). Published May 17, 2018. Accessed March 5, 2026
  6. HIV Vaccine Trials Network (HVTN). Using antibodies for HIV prevention. Accessed March 5, 2026
  7. National Institute of Allergy and Infectious Diseases (NIAID). Sustained ART-free HIV remission. Accessed March 5, 2026
  8. National Institute of Allergy and Infectious Diseases (NIAID). Future directions for HIV treatment research. Accessed March 5, 2026
  9. Grobben M, Stuart RA, van Gils MJ. The potential of engineered antibodies for HIV-1 therapy and cure. Current Opinion in Virology. 2019;38:70-80. doi:10.1016/j.coviro.2019.07.007. Accessed March 5, 2026
  10. Rockefeller University. A Phase 1 study of the safety and pharmacokinetics of the combination of 3BNC117 and 10-1074 in HIV-uninfected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 28, 2016. NLM Identifier: NCT02824536. Accessed March 5, 2026
  11. Rockefeller University. A Phase 2a, randomized study of romidepsin with or without 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 26, 2016. NLM Identifier: NCT02850016. Accessed March 5, 2026
  12. Gruell H, Gunst JD, Cohen YZ, et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. The Lancet Microbe. 2022;3(3):e203-e214. doi:10.1016/S2666-5247(21)00239-1. Accessed March 5, 2026
  13. Aarhus University Hospital. Early administration of latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 20, 2017. NLM Identifier: NCT03041012. Accessed March 5, 2026
  14. Gunst JD, Pahus MH, Rosás-Umbert M, et al. The impact of 3BNC117 and romidepsin treatment at ART initiation on HIV-1 persistence. Webcast presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16, 2022; Virtual. Accessed March 5, 2026
  15. Gunst JD, Pahus MH, Rosás-Umbert M, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med. 2022;28(11):2424-2435. doi:10.1038/s41591-022-02023-7. Accessed March 5, 2026
  16. University of Aarhus. Combining a TLR9 agonist with broadly neutralizing antibodies for reservoir reduction and immunological control of HIV infection: an investigator-initiated randomized, placebo-controlled, Phase IIa trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 7, 2019. NLM Identifier: NCT03837756. Accessed March 5, 2026
  17. Gunst JD, Højen JF, Pahus MH, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med. 2023;29(10):2547-2558. doi:10.1038/s41591-023-02547-6. Accessed March 5, 2026
  18. Gunst JD, Reikvam DH, McMahon JH, et al. The impact of 3BNC117, 10-1074, and lefitolimod on HIV-1 persistence: the TITAN trial. Abstract presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 19-22, 2023; Seattle, WA. Abstract 136. Accessed March 5, 2026
  19. Frontier Biotechnologies Inc. A Phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 22, 2018. NLM Identifier: NCT03719664.Accessed March 5, 2026
  20. Imperial College London. A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated primary HIV infection on viral control off ART. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 2, 2020. NLM Identifier: NCT04319367. Accessed March 5, 2026
  21. Fidler S, Lee M, Collins S, et al. The RIO trial: a randomised placebo-controlled study of 2 LS-bNAbs (3BNC-117-LS & 10-1074-LS) in people treated in early HIV. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 9-12, 2025; San Francisco, CA. Conference Reports for National AIDS Treatment Advocacy Project (NATAP); 2025. Accessed March 5, 2026
  22. Lee MJ, Cherrill LR, Zacharopoulou P, et al. Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial. medRxiv. Published online February 4, 2026:2026.02.04.25342277. doi:10.64898/2026.02.04.25342277. Accessed March 5, 2026
  23. Frontier Biotechnologies Inc. The Phase 2, two arms, one site, safety and antiviral activity of combination therapy with albuvirtide and 3BNC117 in virologically suppressed subjects with HIV-1 infection after analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 22, 2021. NLM Identifier: NCT04819347. Accessed March 5, 2026
  24. Frontier Biotechnologies Inc. A multicenter, two-arm, 24-week study of albuvirtide in combination with 3BNC117 in patients with multi-drug resistant (MDR) HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 17, 2020. NLM Identifier: NCT04560569. Accessed March 5, 2026
  25. Zhou Y, Qin Y, Zhao Q, et al. A multicenter study of albuvirtide combined with 3BNC117 in multidrug-resistant HIV-1 infection. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 9 -12, 2025; San Francisco, CA. Poster 702. Accessed March 5, 2026
  26. ANRS, Emerging Infectious Diseases. A randomised Phase II placebo-controlled trial of antiretroviral therapy (ART) plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 3, 2022. NLM Identifier: NCT05300035. Accessed March 5, 2026
  27. National Institute of Allergy and Infectious Diseases (NIAID). A Phase I/IIa randomized, placebo-controlled trial of conserved-mosaic T-cell vaccine in a regimen with vesatolimod and broadly neutralizing antibodies in adults initiated on suppressive antiretroviral therapy during acute HIV-1. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 5, 2023. NLM Identifier: NCT06071767. Accessed March 5, 2026
  28. Gilead Sciences. A Phase 2 randomized, open-label study to evaluate the safety and efficacy of broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with the capsid inhibitor lenacapavir as long-acting treatment dosed every 6 months in virologically suppressed adults with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 6, 2023. NLM Identifier: NCT05729568. Accessed March 5, 2026
  29. Ogbuagu O, Gaur A, McMahon JH, et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: Phase 2 Week 26 primary outcome. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 9-12, 2025; San Francisco, CA. Conference Reports for National AIDS Treatment Advocacy Project (NATAP); 2025. Accessed March 5, 2026
  30. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. A randomized, double-blind, placebo-controlled study of the combination of two long-acting broadly neutralizing antibodies at ART initiation in adults living with HIV-1 in Sub-Saharan Africa: the ACACIA Study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 4, 2024. NLM Identifier: NCT06205602. Accessed March 5, 2026
  31. University of Oxford. AbVax: combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective T-cell “vaccinal effect” - a randomised Phase II clinical trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 16, 2025. NLM Identifier: NCT07054931. Accessed March 5, 2026
  32. Rockefeller University. An open label, randomized study of the safety and antiretroviral activity of 3BNC117 and 10-1074 in HIV-infected individuals on combination antiretroviral therapy and during analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 3, 2018. NLM Identifier: NCT03526848. Accessed March 5, 2026
  33. Rockefeller University. An open label, single arm study of the safety, pharmacokinetics and antiretroviral activity of the combination of 3BNC117-LS and 10-1074-LS in viremic HIV-infected individuals. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 30, 2020. NLM Identifier: NCT04250636. Accessed March 5, 2026
  34. Luis Montaner. Pilot study on innate activation and viral control in HIV-infected adults undergoing an analytical treatment interruption after administration of pegylated interferon alpha 2b with broadly HIV-1 neutralizing antibodies (3BNC117, 10-1074). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 30, 2018. NLM Identifier: NCT03588715. Accessed March 5, 2026
  35. Gilead Sciences. A Phase 1b randomized, blinded, proof-of-concept study to evaluate the safety and efficacy of broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with capsid inhibitor lenacapavir (GS-6207) in virologically suppressed adults with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 19, 2021. NLM Identifier: NCT04811040. Accessed March 5, 2026
  36. Rockefeller University. An open label, single arm study of the safety and antiretroviral activity of two long-acting broadly neutralizing antibodies plus an IL-15 superagonist in ART-treated adults living with HIV during analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 8, 2022. NLM Identifier: NCT05245292. Accessed March 5, 2026
  37. National Institute of Allergy and Infectious Diseases (NIAID). A randomized placebo-controlled study to evaluate the safety and effects of repeated doses of 3BNC117-LS and 10-1074-LS on persistent viral reservoirs in people living with HIV and on suppressive antiretroviral therapy. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 9, 2022. NLM Identifier: NCT05612178. Accessed March 5, 2026
  38. AIDS Clinical Trials Group. A Phase I, randomized, placebo-controlled study of the safety, antiviral & immunomodulatory activity of broadly neutralizing antibodies 3BNC117-LS-J and 10-1074-LS-J in combination in ART-treated adults in sub-Saharan Africa living with HIV during a monitored analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 14, 2023. NLM Identifier: NCT06031272. Accessed March 5, 2026
  39. National Institute of Allergy and Infectious Diseases (NIAID). A study to evaluate immunologic and virologic parameters during analytical treatment interruption following combination bNAb therapy during suppressive ART. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 1, 2025. NLM Identifier: NCT06908083. Accessed March 5, 2026

Last Reviewed: March 5, 2026